David's practice is predominantly in the areas of chemical and biomedical research tools, including analytical instrumentation, and pharmaceuticals. David's experience in these areas includes GB and European patent prosecution, drafting and international portfolio management for large corporations and universities. David also has significant experience in oppositions and appeals before the EPO. Other subject matter that falls within David's practice includes medical devices, nanotechnology and advanced materials.
David has a degree in Chemistry and a doctorate in Chemistry, as well as a law degree from the University of New South Wales. His research experience included the construction of a novel mass spectrometer, and the application of mass spectrometry to proteomics and analysis of post-translation modification of proteins. His research experience thus covers development of instrumentation and methods of chemical analysis, through to characterisation of biological materials.
David qualified as a solicitor in Sydney, Australia, where he worked in IP litigation and has also qualified as a solicitor in England and Wales. David's practice draws on this combination of scientific and legal experience, with his understanding of enforcement and opposition informing his patent drafting and prosecution, and assisting David in providing commercially focused advice in all areas of his practice.
BSc in Chemistry with Hons 1
Bachelors of laws, UNSW
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.